Corline Biomedical AB (CLBIO) - Total Liabilities
Based on the latest financial reports, Corline Biomedical AB (CLBIO) has total liabilities worth Skr4.82 Million SEK (≈ $518.60K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore CLBIO shareholders equity momentum to track the company's year-over-year net asset growth rate.
Corline Biomedical AB - Total Liabilities Trend (2012–2025)
This chart illustrates how Corline Biomedical AB's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Corline Biomedical AB to measure how efficiently the company converts operating cash flow to free cash.
Corline Biomedical AB Competitors by Total Liabilities
The table below lists competitors of Corline Biomedical AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chia Her Industrial Co Ltd
TW:1449
|
Taiwan | NT$5.09 Billion |
|
Vinyl Chemicals (India) Limited
NSE:VINYLINDIA
|
India | Rs1.03 Billion |
|
Analabs Resources Bhd
KLSE:7083
|
Malaysia | RM305.62 Million |
|
Mereo BioPharma Group PLC ADR
NASDAQ:MREO
|
USA | $6.56 Million |
|
ActRO Co. Ltd
KQ:290740
|
Korea | ₩43.82 Billion |
|
Cytogen Inc
KQ:217330
|
Korea | ₩26.25 Billion |
|
Taiwan Alpha Electronic Co Ltd
TWO:6204
|
Taiwan | NT$157.31 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Corline Biomedical AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Corline Biomedical AB market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 4.27 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Corline Biomedical AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Corline Biomedical AB (2012–2025)
The table below shows the annual total liabilities of Corline Biomedical AB from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr4.82 Million ≈ $518.60K |
-38.60% |
| 2024-12-31 | Skr7.85 Million ≈ $844.57K |
+15.60% |
| 2023-12-31 | Skr6.79 Million ≈ $730.60K |
-5.63% |
| 2022-12-31 | Skr7.19 Million ≈ $774.19K |
-23.69% |
| 2021-12-31 | Skr9.43 Million ≈ $1.01 Million |
+50.83% |
| 2020-12-31 | Skr6.25 Million ≈ $672.60K |
+40.99% |
| 2019-12-31 | Skr4.43 Million ≈ $477.06K |
-44.26% |
| 2018-12-31 | Skr7.95 Million ≈ $855.87K |
+44.57% |
| 2017-12-31 | Skr5.50 Million ≈ $592.00K |
+117.52% |
| 2016-12-31 | Skr2.53 Million ≈ $272.16K |
-32.46% |
| 2015-12-31 | Skr3.74 Million ≈ $402.98K |
-66.83% |
| 2014-12-31 | Skr11.29 Million ≈ $1.21 Million |
+95.96% |
| 2013-12-31 | Skr5.76 Million ≈ $619.91K |
-48.05% |
| 2012-12-31 | Skr11.09 Million ≈ $1.19 Million |
-- |
About Corline Biomedical AB
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting. Its products … Read more